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Abstract
Background: Alpha-synuclein is a key protein in the pathogenesis of Parkinson’s disease. Mutations in the parkin
gene are the most common cause of early-onset autosomal recessive Parkinson’s disease, probably through a
loss-of-function mechanism. However, the molecular mechanism by which loss of parkin function leads to the
development of the disease and the role of alpha-synuclein in parkin-associated Parkinson’s disease is still not
elucidated. Conflicting results were reported about the effect of the absence of parkin on alpha-synuclein-mediated
neurotoxicity using a transgenic approach. In this study, we investigated the effect of loss of parkin on
alpha-synuclein neuropathology and toxicity in adult rodent brain using viral vectors. Therefore, we overexpressed
human wild type alpha-synuclein in the substantia nigra of parkin knockout and wild type mice using two different
doses of recombinant adeno-associated viral vectors.
Results: No difference was observed in nigral dopaminergic cell loss between the parkin knockout mice and wild
type mice up to 16 weeks after viral vector injection. However, the level of alpha-synuclein phosphorylated at serine
residue 129 in the substantia nigra was significantly increased in the parkin knockout mice compared to the wild
type mice while the total expression level of alpha-synuclein was similar in both groups. The increased
alpha-synuclein phosphorylation was confirmed in a parkin knockdown cell line.
Conclusions: These findings support a functional relationship between parkin and alpha-synuclein phosphorylation
in rodent brain.
Keywords: Parkinson’s disease, Alpha-synuclein, Alpha-synuclein phosphorylation, Parkin, Adeno-associated viral
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Background
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder. Neuropathologically, it is
characterized by the progressive loss of dopaminergic
neurons in the substantia nigra (SN) and the presence of
proteinaceous intracellular inclusions called Lewy bodies
(LBs) and Lewy neurites in the surviving neurons [1]. Al-
though the etiology of sporadic PD remains still unclear,
the discovery of genes linked to familial forms of the dis-
ease has improved our understanding of the pathogenic
mechanisms leading to PD.
Point mutations and multiplications of the α-synuclein
(α-SYN) gene, SNCA, cause a rare familial autosomal
dominant form of PD [2]. α-SYN is a small protein of
140 amino acids that is widely expressed in the brain
and localizes predominantly to presynaptic terminals [3].
The biological function of α-SYN remains unknown, al-
though it’s involvement in dopamine transmission and
biosynthesis [4,5], synaptic plasticity [6] and turnover of
synaptic vesicles has been suggested [7]. Under pathological
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conditions, including mutations and increased expression
levels, α-SYN has the propensity to adopt a β-sheet rich
conformation which leads to the formation of oligomers
and fibrillar aggregates [8]. This fibrillar form of α-SYN is
the main protein component of LBs and Lewy neurites, in-
dicating that α-SYN plays a crucial role in the pathogen-
esis of PD [9]. Moreover, animal models based on
overexpression of wild type (WT) or mutant α-SYN, re-
capitulate some of the main hallmarks of PD, including
neurodegeneration, motor dysfunction and inclusion for-
mation [10].
Mutations in the parkin gene are the major cause of
early-onset autosomal recessive PD [11]. Parkin has been
identified as an E3 ubiquitin-ligating enzyme, catalyzing
the attachment of ubiquitin to substrate proteins, which
consequently leads to their proteasomal degradation
[12-14]. It was therefore suggested that the loss of parkin
function due to disease-causing mutations might damage
neurons through the accumulation of toxic proteins. On
the other hand, evidence is accumulating that parkin ubi-
quitin ligase activity also contributes to non-degradative
poly- and mono-ubiquitination, which are involved in al-
ternative cellular pathways, including mitochondrial qual-
ity control [15] and signal transduction cascade activation
[16,17]. However, the molecular mechanism by which loss
of parkin function leads to the development of PD is still
not completely elucidated. More specifically, the role of α-
SYN in parkin-associated PD remains unclear, although
there are lines of evidence suggesting a potential link be-
tween parkin and α-SYN. On one hand it has been re-
ported that the unmodified form of α-SYN does not
interact with parkin [18] and no accumulation of α-SYN
was detected in the brain of parkin knockout (parkin−/−)
mice [19-21]. On the other hand, in about two thirds of
the seventeen neuropathological reports of patients with
parkin mutations published to date, no LBs were found,
indicating that parkin might play a role in LB forma-
tion[22]. Furthermore, overexpression of parkin provides
protection against α-SYN toxicity in a variety of cellular
and animal models [23-29]. Conflicting results were pub-
lished in a number of studies using a transgenic approach
to investigate the effect of parkin on α-SYN-induced
neurotoxicity. The neurodegenerative phenotype was un-
expectedly delayed in the absence of parkin in A30P α-
SYN transgenic mice [30], while no effect of loss of parkin
on neuropathology was found in A53T α-SYN transgenic
mice [31]. In a third publication, an increase in damaged
mitochondria in neurons of the SN and a reduction of
complex I activity was reported in old double mutant mice
generated by the crossing of parkin−/− mice with double
mutated A53T and A30P α-SYN overexpressing mice [32].
However, these results in transgenic mice showed that the
absence of parkin did not clearly affect α-SYN-induced
neurodegeneration, except for some minor changes.
In the present study, we chose an alternative approach to
investigate the effect of the absence of parkin on α-SYN-
induced cell death in adult rodent brain using viral vector
technology. Therefore, we overexpressed human WT α-
SYN in the SN of parkin−/− and wild type (parkin+/+) mice
with recombinant adeno-associated viral (rAAV) vectors.
Subsequently, we analyzed the degree of neurodegeneration
and synucleinopathy in the SN of those mice.
Results
Absence of parkin does not increase the sensitivity to
dopaminergic degeneration induced by a high dose of
rAAV2/7-WT α-SYN
In a previous study, we showed that rAAV2/7-mediated
overexpression of WT α-SYN in the SN of mice resulted
in a dose-dependent, progressive dopaminergic neurode-
generation [33]. Therefore, to study the effect of the ab-
sence of parkin on α-SYN induced dopaminergic cell
death, in a first experiment we stereotactically injected a
rAAV2/7 vector encoding WT α-SYN in the right SN of
adult parkin−/− and parkin+/+ mice at a vector titer of
4E + 11 genome copies (GC)/ml (high vector titer, see
experimental design in Table 1).The animals were ana-
lyzed at 1 week and 4 weeks after injection. As add-
itional control, a group of parkin−/− and parkin +/+ mice
was injected with a similar titer of rAAV2/7 vector cod-
ing for enhanced green fluorescent protein (eGFP).
Immunohistochemical stainings for α-SYN and eGFP
revealed high transgene expression in the SN for both
vectors (Figure 1). With confocal analysis we observed a
transduction efficiency of the dopaminergic neurons of
approximately 85% (Figure 2). To investigate the degree
of dopaminergic neurodegeneration, we stereologically
quantified the number of tyrosine hydroxylase (TH)-
positive cells in the SN. At 4 weeks after injection, the
rAAV2/7-WT α-SYN induced a dopaminergic lesion of
59 ± 6% compared to the non-injected side in the parkin
+/+ mice, which is in agreement with our previous study
[33] (Figure 1 and 3A). In the parkin−/− mice a compar-
able dopaminergic cell loss of 52 ± 6% was observed.
The rAAV2/7-eGFP injected mice did not show any loss
of TH-positive cells (Figure 1 and 3B). The loss of dopa-
minergic terminals in the striatum was comparable be-
tween parkin+/+ (24 ± 5.2%) and parkin−/− (33 ± 6.9%) mice
(Figure 3C). Thus, we conclude that the sensitivity of par-
kin−/− mice and parkin+/+ mice to dopaminergic degener-
ation induced by a high dose of rAAV2/7-WT α-SYN is
similar.
Overexpression of α-SYN with rAAV2/7 increases
phosphorylation of α-SYN at serine residue 129 in parkin
−/− mice compared to parkin+/+ mice
In a next step, we determined the number of cells in the
SN that were positive for α-SYN phosphorylated at serine
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Table 1 Experimental design
Group
Analysis time point (Immunohistochemistry) rAAV2/7-WT αSYN rAAV2/7-eGFP rAAV2/7-WT αSYN
(4E + 11 GC/ml) (4E + 11 GC/ml) (1E + 11 GC/ml)
high α-SYN dose low α-SYN dose
parkin+/+ parkin−/− parkin+/+ parkin−/− parkin+/+ parkin−/−
1 week n = 4 n = 4 n = 2 n = 3
4 weeks n = 15 n = 16 n = 5 n = 6 n = 10 n = 13
8 weeks n = 6 n = 5
16 weeks n = 6 n = 6
Adult 2 to 4-month-old parkin+/+ and parkin−/− mice were stereotactically injected in the right SN with 2 μl of rAAV2/7-WT α-SYN vector at a titer of 4E + 11 GC/ml
(high α-SYN dose) or 1E + 11 GC/ml (low α-SYN dose) or rAAV2/7-eGFP vector at a titer of 4E + 11 GC/ml. At the mentioned time points after injection, animals
were perfused for immunohistochemical analysis.
Figure 1 Overexpression of α-SYN or eGFP in mouse SN with high titer rAAV2/7 vectors. Immunohistochemical staining for TH (left panels) shows
cell loss in the injected side of both the parkin−/− and the parkin+/+ mice at 4 weeks after injection with a high titer of rAAV2/7-WT α-SYN.
Immunohistochemical stainings for α-SYN and eGFP (middle and right panels) show wide expression of these proteins in the injected side of the
SN. Right panels are magnifications of the adjacent left panel. Scale bars overviews = 400 μm and magnifications = 50 μm.
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residue 129 (P-S129), a form of α-SYN which is considered
to be the pathological form of α-SYN and the most abun-
dant modification of α-SYN in LBs [34,35]. Therefore, we
performed an immunohistochemical staining with an anti-
body specifically recognizing this phosphorylated form of
α-SYN [34] and stereologically quantified the number of
positive cells in the injected side of the whole SN. No P-
S129 positive cells were observed in the non-injected side
of the SN, indicating that only phosphorylation of the
overexpressed human α-SYN is within the limits of detec-
tion. At 1 week after injection, no difference was observed
between parkin−/− mice (3563 ± 259 cells) and parkin+/+
mice (3371 ± 416 cells). At 4 weeks after injection, the
number of cells positive for P-S129 α-SYN was increased
in both groups when compared to 1 week. Interestingly,
this number was significantly higher in the parkin−/− mice
(7632 ± 291 cells) than in the parkin+/+ mice (6288 ± 495
cells) (p = 0,027) (Figure 4A-B). This higher number of P-
S129 α-SYN positive cells in the parkin−/− mice was not
caused by higher expression levels of α-SYN, since the
total number of α-SYN positive cells in the SN was similar
in the parkin+/+ and parkin−/− mice at both time points
(Figure 4C). Differences in the affinities of the P-S129 α-
SYN antibody and α-SYN antibody explain the apparent
lower number of α-SYN positive cells compared to the
number of P-S129 α-SYN positive cells. We also stained
the striatum for P-S129 α-SYN to check if the dopamin-
ergic terminals also contain phosphorylated α-SYN. We
Figure 2 High transduction efficiency of mouse dopaminergic neurons with rAAV2/7-WT α-SYN and rAAV2/7-eGFP. Fluorescent double stainings
for TH and α-SYN at 1 week or TH and eGFP at 4 weeks after injection of rAAV2/7-WT α-SYN or rAAV2/7-eGFP respectively, demonstrate that the
majority of the dopaminergic neurons of the injected side of the SN is transduced. Scale bar = 25 μm.
Figure 3 A high dose of rAAV2/7-WT α-SYN induces similar dopaminergic degeneration in parkin−/− and parkin+/+ mice. Stereological
quantification of the number of TH-positive neurons in the SN of parkin+/+ and parkin−/− mice at (A) 1 week and 4 weeks after injection with a
high titer of rAAV2/7-WT α-SYN and at (B) 4 weeks after injection with rAAV2/7-eGFP. (C) quantification of TH staining in striatum (injected over
non-injected side) of parkin+/+ and parkin−/− mice 4 weeks after injection. Asterisks depict significant decrease respective to 1 week, unless
specified otherwise. (Mean ± SEM, two-way ANOVA followed by Bonferroni post-hoc test, ** p < 0.01 ***p < 0.001, 1 week rAAV2/7-WT α-SYN:
n = 4; 4 weeks rAAV2/7-WT α-SYN: n = 15-16; 4 weeks rAAV2/7-eGFP: n = 5-6).
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Figure 4 (See legend on next page.)
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detected P-S129 α-SYN-positive neuritic inclusions
(Figure 4E) but no difference in the number of these inclu-
sions was observed between parkin+/+ and parkin−/− mice
at 4 weeks after injection (Figure 4D).
A low dose of rAAV2/7-WT α-SYN induces slower but
similar dopaminergic degeneration and increased α-SYN
phosphorylation in parkin−/− mice
The enhanced phosphorylation of α-SYN in the parkin−/−
mice observed in the previous experiment was not paral-
leled by an increase in dopaminergic cell death. We rea-
soned that this might be due to the very fast and robust
degenerative process, precluding the detection of subtle
differences. Therefore, we decided to repeat the experi-
ment with a 4 times lower dose of rAAV2/7-WT α-SYN
(1E + 11 GC/ml, low vector titer). In this experiment,
animals were analyzed at 1 week, 4 weeks, 8 weeks and
16 weeks after injection (see experimental design in
Table 1).
As expected, stereological quantification of the num-
ber of surviving dopaminergic neurons revealed a milder
dopaminergic cell loss at 4 weeks (approximately 40%)
compared to the high titer of rAAV2/7-WT α-SYN. At
8 weeks and 16 weeks, in both groups the dopaminergic
degeneration was not further progressive, suggesting that
with the low titer of rAAV2/7-WT α-SYN the maximum
amount of degeneration was already reached at 4 weeks
after injection. However, the TH-positive cell loss was
again comparable between the parkin−/− and parkin+/+
mice at all time points (e.g. at 4 weeks 35 ± 7% and 41 ±
5% TH-positive cell loss, respectively compared to the
non-injected side) (Figure 5A-B). These results confirm
that the absence of parkin does not alter the susceptibility
to α-SYN induced dopaminergic cell death.
We also investigated the effect of absence of parkin on
α-SYN phosphorylation in the low dose α-SYN set-up.
The number of P-S129 α-SYN positive cells in the injected
side progressively increased over time until 8 weeks and
remained stable at 16 weeks after viral vector delivery to
the SN (Figure 6A-B). Here again, we observed a sig-
nificantly higher level of α-SYN phosphorylation in
the parkin−/− mice compared to the parkin+/+ mice at
8 weeks and 16 weeks after injection (respectively
9389 ± 337 cells versus 7263 ± 532 cells at 8 weeks, p =
0,0179; 7954 ± 518 cells versus 6000 ± 313 cells at 16 weeks,
p = 0,009). Immunohistochemical staining for α-SYN con-
firmed expression of α-SYN up to 16 weeks after injection
(Figure 6C). As seen before, the total number of α-SYN
positive cells was similar in the parkin−/− mice and the
parkin+/+ mice at the 4 different time points (Figure 6D).
To investigate the mechanism behind this increased α-
SYN phosphorylation in the absence of parkin we induced
stable parkin knockdown using microRNA (miR)-based
lentiviral vectors in human SHSY5Y neuroblastoma cells
overexpressing WT human α-SYN. Two miRparkin lenti-
viral vectors induced efficient knockdown of parkin as
shown by Q-RT-PCR (data not shown) and Western blot-
ting (Figure 7). In agreement with the in vivo data we
observed an increase of α-SYN phosphorylation at serine
residue 129 without affecting the total α-SYN levels in cell
culture (Figure 7). Since Polo-Like-Kinase-2 (PLK2) was
shown to phosphorylate α-SYN at S129 [36] and protein
phosphatase-2A (PP2A) is a known α-SYN phosphatase
at S129 [37], we verified the levels of PLK2 and PP2A in
both parkin knockdown and the control cell lines but no
differences were observed in expression of either protein
(Figure 7).
We can conclude that overexpression of α-SYN in the
absence of parkin enhances phosphorylation of α-SYN at
serine residue 129 but does not affect the degree of
dopaminergic neurodegeneration.
Discussion
This study was designed to investigate the effect of the
loss of parkin on α-SYN induced neurotoxicity in rodent
brain. We found that the absence of parkin did not alter
the vulnerability of dopaminergic neurons to WT α-SYN
induced neurodegeneration. However, the number of P-
S129 α-SYN positive cells in the SN of parkin−/− mice
was increased compared to parkin+/+ mice. This increase
in the number of P-S129 α-SYN positive cells in the par-
kin−/− mice was not due to differences in expression
level of α-SYN, since the total number of α-SYN-positive
cells was similar in both groups, These results were repro-
duced in a second, independent experiment performed
with a 4 times lower titer of rAAV2/7-WT α-SYN.
(See figure on previous page.)
Figure 4 Increased phosphorylation of α-SYN at S129 in parkin−/− mice compared to parkin+/+ mice. (A) Representative images of P-S129 α-SYN
expression in the SN of parkin−/− and parkin+/+ mice at 1 week and 4 weeks after injection with a high titer of rAAV2/7-WT α-SYN. Right panels
are magnifications of the overviews of the injected side (middle panels). Scale bar overviews = 400 μm and magnifications = 50 μm. (B) Stereological
quantification of the number of P-S129 α-SYN positive cells in the injected side of the SN of parkin+/+ and parkin−/− mice at 1 week (n = 4)
and 4 weeks (n = 15-16) after injection with a high titer of rAAV2/7-WT α-SYN. (Mean ± SEM, two-way ANOVA followed by Bonferroni post-hoc
test, # p < 0.05 versus parkin+/+, **p < 0.01 versus 1 week, ***p < 0.001 versus 1 week). (C) Stereological quantification of the number of α-SYN
positive cells in the injected side of the SN of parkin+/+ and parkin−/− mice at 1 week (n = 4) and 4 weeks (n = 15-16) after injection with a
high titer of rAAV2/7-WT α-SYN. (Mean ± SEM). (D) Quantification of the number of P-S129 α-SYN positive neuritic inclusions in the striatum at
4 weeks (n = 14–15, Mean ± SEM). (E) Picture of the P-S129 α-SYN staining in the striatum (left: 10 x) and magnification (right: 40 x) of neuritic
inclusions. Scale bar = 50 μm.
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A number of previous studies already addressed the
question if the absence of parkin affects the development
of α-synucleinopathy using a transgenic strategy. How-
ever, inconsistent results were reported, since in one
study no effect was found in A53T α-SYN transgenic
mice [31], whereas in a second study the loss of parkin
unexpectedly mitigated the α-SYN phenotype in A30P
α-SYN transgenic mice [30]. In the present study, we
opted for an alternative approach with viral vector-
mediated overexpression of WT α-SYN in the SN of
parkin−/− and parkin+/+ mice. rAAV vectors are an at-
tractive tool for gene delivery in the brain, since they
provide several advantages: specific brain regions can be
targeted, the transduction efficiency in dopaminergic
neurons is high, and a long-lasting and stable expression
of the transgene at different doses can be achieved with a
single delivery [38]. In addition, in a previous study in our
own research group, we showed that rAAV2/7-mediated
WT α-SYN overexpression in mouse SN leads to a dose-
dependent, progressive dopaminergic cell death [33].
With our strategy, we did not observe a difference in
sensitivity to WT α-SYN induced dopaminergic cell death
between parkin−/− and parkin+/+ mice. The strength of our
study is that it allowed us to specifically investigate the sen-
sitivity of the dopaminergic cell population to α-SYN tox-
icity in the absence of parkin. Since the majority of α-SYN
transgenic mice do not develop a robust dopaminergic
phenotype, they are less suitable to study the effect of par-
kin deficiency and α-synucleinopathy in nigral dopamin-
ergic neurons [39,40]. On the other hand, our finding that
loss of parkin does not exacerbate dopaminergic degener-
ation is partly consistent with the results in the transgenic
mice, since in those studies, no difference in dopaminergic
cell survival was found between the α-SYN overexpressing
mice and the parkin−/− - α-SYN double transgenic mice, in-
dicating that the complete absence of parkin does not affect
dopaminergic cell survival [30,31]. A possible explanation
for this somewhat unexpected observation might be the
presence of compensatory mechanisms in the parkin−/−
mice, which may counterbalance for the total loss of parkin
protein occurring already during embryonic development.
Reports of an increased sensitivity of striatal metabotropic
glutamate receptors and elevated levels of reduced glutathi-
one in parkin−/− mice indicate that such compensatory ad-
aptations exist [41,42]. Locoregional downregulation of
parkin with viral vectors or the generation of conditional
parkin knockout animals may be a valuable strategy to
overcome this issue. Indeed, it was recently reported that
adult depletion of parkin in the SN of conditional parkin−/−
mice resulted in a progressive loss of dopaminergic neurons
up to 40%, a phenotype that has never been observed in
the constitutive parkin−/− mice [21,43].
The lack of increased vulnerability of parkin−/− mice to
WT α-SYN induced dopaminergic cell death was observed
Figure 5 A low dose of rAAV2/7-WT α-SYN induces similar dopaminergic degeneration in parkin−/− and parkin+/+ mice. (A) Representative images of
immunohistochemical staining for TH in the SN at 1 week, 4 weeks, 8 weeks and 16 weeks after injection with a low titer of rAAV2/7-WT α-SYN. Scale
bar = 400 μm. (B) Stereological quantification of the number of TH-positive neurons in the SN of parkin+/+ and parkin−/− mice at 1 week, 4 weeks,
8 weeks and 16 weeks after injection with a low titer of rAAV2/7-WT α-SYN. (Mean ± SEM, two-way ANOVA followed by Bonferroni post-hoc test, *p <
0.05, **p < 0.01, n = 2-3 at 1 week, n = 10-13 at 4 weeks, n = 5-6 at 8 weeks, n = 6 at 16 weeks).
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Figure 6 Increased P-S129 α-SYN in parkin−/− mice after injection with a low titer of rAAV2/7-WT α-SYN. (A) Representative images of P-S129 α-SYN
expression in the SN of parkin−/− and parkin+/+ mice at 1 week, 4 weeks, 8 weeks and 16 weeks after injection with a low titer of rAAV2/7-WT α-SYN.
Right panels are magnifications of the overview of the injected side (middle panels). Scale bar overviews = 400 μm and magnifications = 50 μm.
(B) Stereological quantification of the number of P-S129 α-SYN positive cells in the injected side of the SN of parkin+/+ and parkin−/− mice at 1 week
(n = 2-3), 4 weeks (n = 10-13), 8 weeks (n = 5-6) and 16 weeks (n = 6) after injection. Asterisks depict significant increase respective to 1 week, unless
specified otherwise. (Mean ± SEM, two-way ANOVA followed by Bonferroni post-hoc test, student’s T-test followed by Benjamini-Hochberg to compare
parkin+/+ and parkin−/− separately at the different time points, *p < 0.05, **p < 0.01, ***p < 0.001). (C) Representative images of α-SYN expression in the
SN of parkin−/− and parkin+/+ mice at 1 week, 4 weeks, 8 weeks and 16 weeks after injection with a low titer of rAAV2/7-WT α-SYN. Right panels are
magnifications of the overview of the injected side (middle panels). Scale bar overviews = 400 μm and magnifications = 50 μm. (D) Stereological
quantification of the number of α-SYN positive cells in the injected side of the SN of parkin+/+ and parkin−/− mice at 1 week (n = 2-3), 4 weeks
(n = 10-13), 8 weeks (n = 5-6) and 16 weeks (n = 6) after injection with a low titer of rAAV2/7-WT α-SYN. (Mean ± SEM).
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with two different doses of WT α-SYN. In the second ex-
periment, we opted for a lower dose, because we reasoned
that the dramatic dopaminergic cell loss achieved with the
highest dose of WT α-SYN might hide small differences in
sensitivity between parkin−/− and parkin+/+ mice. Al-
though the lower dose of WT α-SYN resulted in a milder
dopaminergic cell death, the degree of degeneration was
still considerable (approximately 40% at 4 weeks). There-
fore, we cannot exclude that subtle differences in sensitiv-
ity might emerge when using even lower overexpression
of α-SYN or at later time points than analyzed in this
study.
In a next step, we wondered whether the absence of par-
kin would influence the phosphorylation of α-SYN at
serine residue 129, since the level of P-S129 α-SYN is
highly elevated in the brains of PD patients [34,35]. We
found that the number of nigral cells positive for P-S129
α-SYN was significantly higher in the parkin−/− mice com-
pared to parkin+/+ mice. This was not the case for the
dopaminergic terminals in the striatum. This discrepancy
might suggest that mainly the non-dopaminergic neurons
show an increased phosphorylation in the parkin−/− mice
or that the dopaminergic neurons with increased P-S129
α-SYN have relatively lower terminal densities. This in-
creased phosphorylation is in apparent contradiction with
the findings of Lo Bianco et al. who reported an increase
in P-S129 α-SYN positive aggregates after overexpression
of parkin together with A30P α-SYN in the rat SN using
lentiviral vectors [25]. That observation was associated
with a protective effect of parkin overexpression on A30P
α-SYN induced dopaminergic degeneration. Furthermore,
no increase in P-S129 α-SYN abundance was noticed in
A30P α-SYN transgenic mice on a parkin−/− background
[30]. On the contrary, and in agreement with our results,
lentiviral vector-mediated co-expression of parkin with
WT α-SYN in the striatum of rats reduced the levels of P-
S129 α-SYN [24]. A similar result was found in the stri-
atum of macaque monkeys when parkin and WT α-SYN
were overexpressed by means of rAAV vectors, although
in this study a decrease in total α-SYN was also reported
[29]. In the study with the A53T α-SYN transgenic mice
crossed with parkin−/− mice phosphorylation of α-SYN
has not been investigated [31]. So far, we cannot clearly
explain the inconsistencies between these reports, al-
though the most obvious explanation is differences in ex-
perimental conditions. Altogether, the studies performed
with WT α-SYN, including ours, point towards a correl-
ation between decreased levels of parkin and increased
phosphorylation of α-SYN at S129, whereas in the studies
with mutant A30P α-SYN either the reverse or no effect is
suggested. Thus, it is possible that the influence of parkin
on S129-phosphorylation is different for WT α-SYN than
for A30P α-SYN, since the two forms also differ in other
properties including aggregation [44] and membrane-
binding [45].
At this point, we can only speculate about the mech-
anism behind the increased phosphorylation of WT α-
SYN in the absence of parkin. No direct binding of
parkin to P-S129 α-SYN was observed in brain extracts
of A30P α-SYN transgenic mice [30]. We also quantified
the percentage of ubiquitin and α-SYN double-positive
cells but no difference was seen between parkin+/+ and
parkin−/− mice (data not shown). This suggests that the
increased phosphorylation of WT α-SYN is not a conse-
quence of a difference in ubiquitination of α-SYN. It is
possible that parkin modulates kinases and phosphatases
regulating the phosphorylation of α-SYN at S129. In
agreement with this hypothesis it was reported that
overexpression of α-SYN in the brain of rats resulted in
an increase in the level of Polo-Like-Kinase-2 (PLK2)
and this increase was annihilated when parkin was co-
expressed with α-SYN [24]. Absence of parkin might
then result in a more pronounced increase in PLK2
levels and therefore increased S129 phosphorylation of
α-SYN, since PLK2 is known to phosphorylate α-SYN at
S129 [36]. We performed stainings for PLK2 on brain
sections, but we failed to reliably detect endogenous ex-
pression levels of PLK2 (data not shown). Therefore we
induced stable parkin knockdown in human SHSY5Y
neuroblastoma cells overexpressing WT α-SYN. Interest-
ingly, the increased S129 phosphorylation of α-SYN after
parkin knockdown was replicated in this cell culture
Figure 7 Increased P-S129 α-SYN in human SHSY5Y neuroblastoma
cells after parkin knockdown. Western blotting against PLK2, parkin,
PP2A, P-Ser129 α-SYN and α-SYN. The miRs against parkin induced
both parkin knockdown and an increase in P-Ser129 α-SYN signal
without affecting α-SYN, PLK2 and PP2A levels. A miR against firefly
luciferase (Fluc) was used as control.
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model, without effect on total α-SYN level. However,
PLK2 protein levels were not altered after parkin knock-
down in cell culture. Another potential mechanism in-
volves protein phosphatase-2A (PP2A) that has been
shown to dephosphorylate α-SYN at S129 [37]. Indeed,
the level of protein phosphatase-2A (PP2A) was reportedly
increased when parkin was co-expressed with α-SYN
compared to expression of α-SYN alone in rat striatal ex-
tracts [24]. Absence of parkin might then decrease PP2A
levels in these conditions, resulting in increased S129
phosphorylation of α-SYN. However, we failed to detect
alterations in PP2A expression in the parkin knockdown
cells. Thus, our data suggest that the mechanism behind
the increased α-SYN phosphorylation might be independ-
ent from the PLK2 or PP2A pathway, although we cannot
exclude changes in activity of either PLK2 or PP2A.
Furthermore, it has been demonstrated that 26S protea-
somal activity is decreased in parkin−/− mice and parkin
null Drosophila [46]. Also proteasomal dysfunction and
S129 phosphorylation of α-SYN have been linked before.
First, two independent studies describe that proteasomal
inhibition increases casein kinase 2 activity, another kinase
mediating phosphorylation of α-SYN at S129 [47], result-
ing in enhanced S129 phosphorylation of α-SYN [48,49].
Second, it was demonstrated that inhibition of the prote-
asome pathway resulted in the accumulation of P-S129 α-
SYN without alteration in the total levels of α-SYN,
suggesting that P-S129 α-SYN specifically undergoes deg-
radation by the proteasome pathway [50].
In the present study, the increased level of P-S129 α-
SYN in the parkin−/− mice was not associated with in-
creased dopaminergic degeneration, which is intuitively
in contradiction with the knowledge that ± 90% of α-
SYN within LBs from PD patients is phosphorylated at
S129 [34,35]. The toxicity of P-S129 α-SYN in vivo has
been studied extensively in the last years using mutated
forms of α-SYN in which S129 is replaced either with an
aspartate (S129D), to mimic phosphorylation or with an
alanine (S129A), to block phosphorylation. However,
conflicting results were reported. Expression of S129D
α-SYN in Drosophila resulted in an enhanced toxicity,
whereas no dopaminergic cell loss was observed if
S129A α-SYN was expressed [51]. On the contrary,
Caenorhabditis elegans overexpressing S129A α-SYN
showed severe motor dysfunction and synaptic abnor-
malities, unlike worms overexpressing S129D α-SYN
that exhibited a nearly normal phenotype [52]. Two
studies using rAAV vectors in rats found expression of
S129A α-SYN to be more toxic than S129D α-SYN
[53,54]. In a third study, there was no difference between
the two forms of α-SYN [55]. In a recent study, S129D
α-SYN expression in rat SN resulted in an accelerated
striatal dopaminergic fiber loss and an earlier appearance
of motor deficits compared to S129A α-SYN, although
the nigral degeneration was similar [56]. However, the
S129D mutant might not completely mimick the constitu-
tively phophorylated α-SYN. In another study phosphoryl-
ation of A53T α-SYN was induced by rAAV-mediated
overexpression of G-protein-coupled receptor kinase 6 in
rats, which resulted in accelerated A53T α-SYN induced
neurodegeneration [57], in contrast to our data. Species
differences might be involved, since we observed that rats
are more sensitive to rAAV-α-SYN-induced neurodegen-
eration compared to mice [33,58]. Altogether, the role of
S129 phosphorylation of α-SYN in neurodegeneration still
remains unclear.
Conclusions
In the present study, we have shown that the vulnerabil-
ity of mouse dopaminergic neurons to α-SYN toxicity is
not altered in the absence of parkin, but that the loss of
parkin enhances phosphorylation of α-SYN at S129.
Additional studies will be required to elucidate the mo-
lecular mechanism behind our findings and the signifi-
cance for the pathogenesis of parkin-associated PD.
Methods
Cloning of rAAV vector plasmids
The plasmids for the rAAV vector production were pre-
viously described [38,59]. These plasmids include the
construct for the AAV2/7 serotype, the AAV transfer
plasmid and the pAdvDeltaF6 adenoviral helper plasmid.
The transfer plasmids encoded as transgene eGFP or
human WT α-SYN. The transgenes were under the con-
trol of the CMVie-enhanced Synapsin1 promotor.
Recombinant rAAV vector production and purification
Vector production and purification were performed as
previously described [38]. Briefly, the triple transfection
into HEK293T cells was carried out using linear poly-
ethylenimine solution. Vector particles were harvested
from the supernatant and concentrated using tangential
flow filtration. The concentrated supernatant was further
purified using a discontinuous iodixanol step gradient.
The final sample was aliquoted and stored at −80°C.
Characterization of the rAAV stocks included real-time
quantitative PCR analysis for genomic copy determin-
ation (presented as GC/ml) and silver-stained sodium
dodecyl sulfate-polyacrylamide gel electrophoresis ana-
lysis for vector purity.
Animals and stereotactic neurosurgery
All animal experiments were carried out in accordance
with the European Communities Council Directive of 24
November 1986 (86/609/EEC) and approved by the Bio-
ethical Committee of the KU Leuven (Belgium).
The transgenic parkin−/− mice carry a homozygous dele-
tion of exon 3 [41]. Parkin+/+ mice in the whole first 'high
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α-SYN dose’ experiment (n = 19), including rAAV2/7-
eGFP (n = 5), and part in the second ‘low α-SYN dose’
experiment (1 week all and 4 weeks: 6 out of 10) were
age- and gender-matched C57BL/6 J mice (Janvier, Le-
Genest-Saint-Isle, France) (see Table 1). Rest of parkin+/+
mice in the ‘low α-SYN dose’ experiment were age- and
gender-matched wild type littermates. Parkin genotyping
was performed as described in [30]. No differences were
observed in number of TH-positive cells, Ser-129-P α-
SYN positive cells and α-SYN positive cells between the
C57Bl6 mice and wild type littermates at 4 weeks after in-
jection with the low titer of rAAV2/7-WT α-SYN (data
not shown). Therefore, we concluded that potential minor
differences in background did not influence our outcome.
The age of the mice was 2 months in the first experiment
and varied between 2 and 4 months in the second experi-
ment. The mice were housed under a normal 12-h light/
dark cycle with free access to pelleted food and tap water.
All surgical procedures were performed using aseptic
techniques and ketamine (75 mg/kg IP, KETALAR®, Pfizer,
Elsene, Belgium) and medetomidine (1 mg/kg, DORMI-
TOR®, Pfizer) anesthesia. Following anesthesia the mice
were placed in a stereotactic head frame (Stoelting Co,
Wood Dale, IL, USA). The skull was exposed by a midline
incision and a small hole was drilled in the appropriate lo-
cation, using bregma as reference point. 2 μl of rAAV
vector were injected at a rate of 0.25 μl/min with a 30-
gauge needle on a 10 μl Hamilton syringe. Stereotactic co-
ordinates used for the right mouse SN were anteroposter-
ior −3.1 mm and medio-lateral −1.2 mm relative to
bregma, and dorsoventral −4.0 mm, from the dura surface.
The needle was left in place for an additional 5 min be-
fore being slowly retracted. After surgery, anesthesia
was reversed with an intraperitoneal (IP) injection of
atipamezol (0.5 mg/kg, ANTISEDAN®, Pfizer).
Histology
At different time points after injection, animals were
deeply anesthetized with an IP injection of pentobarbital
(60 mg/kg, NEMBUTAL®, CEVA Santé Animale,
Libourne, France) and transcardially perfused with phos-
phate buffered saline (PBS) followed by ice-cold 4%
paraformaldehyde. After removal of the brain and over-
night postfixation, 50 μm thick coronal sections were
cut using a vibrating microtome (HM 650 V, Microm,
Walldorf, Germany) and stored at 4 °C. Immunohisto-
chemistry was performed under uniform conditions on
free-floating sections using antibodies raised against eGFP
(rabbit polyclonal 1:10000, in-house), TH (rabbit polyclonal
1:5000, Millipore AB152, Darmstadt, Germany), α-SYN
(rabbit polyclonal 1:5000, Millipore AB5038) or P-S129 α-
SYN (mouse monoclonal 1:5000, 11A5, Anderson et al.
2006 [34]; Elan Pharmaceuticals, South San Francisco, CA,
USA). Sections were pretreated with 3% hydrogen peroxide
for 10 min and incubated overnight with primary antibody
in 10% normal goat or swine serum (DakoCytomation,
Heverlee, Belgium). As secondary antibody, we used bio-
tinylated anti-rabbit or anti-mouse IgG (1:600 (α-SYN),
1:300 (others), DakoCytomation), followed by incubation
with streptavidin-horseradish peroxidase complex (1:1000,
DakoCytomation). eGFP, α-SYN and P-S129 αSYN immu-
noreactivity was visualized using 3,3-diaminobenzidine
(0,4 mg/ml, Sigma-Aldrich, St. Louis, MO, USA). TH im-
munoreactivity was visualized using Vector SG (SK-4700,
Vector laboratories, Burlingame, CA) as a chromogen.
After being rinsed and mounted, sections were coverslipped
with DPX (Sigma-Aldrich).
For fluorescent double staining, sections were rinsed
three times in PBS and then incubated overnight in PBS-
0.1% triton X-100, 10% goat serum, and the following anti-
bodies: TH (mouse monoclonal 1:500, Merck Millipore
MAB318), eGFP (rabbit polyclonal 1:1000, in-house) and
α-SYN (rabbit polyclonal 1:1000, Millipore AB5038). After
three rinses in PBS-0.1% triton X-100 the sections were in-
cubated in the dark for 2 h in fluorochrome-conjugated
secondary antibodies: goat anti-rabbit Alexa 488 (1:500,
Molecular Probes™, Invitrogen, Gent, Belgium) and goat
anti-mouse Alexa 555 (1:500, Molecular Probes™, Invitro-
gen). After being rinsed in PBS and mounted, the sections
were coverslipped with Mowiol. Fluorescent double stain-
ing for TH and eGFP or α-SYN was visualized by confocal
laser scanning microscopy (Fluoview FV1000, Olympus,
Tokyo, Japan) using a 40x lens.
Stereological quantification
The total number of immunoreactive positive cells in
the SN was estimated by stereological measurements
using the optical fractionator method in a computerized
system (StereoInvestigator; MicroBright-Field, Magde-
burg, Germany) and a Leica DMR optical microscope as
described before [60]. The SN pars compacta was delin-
eated based on visual observation and morphology. Every
fifth section throughout the rostro-caudal extent of the
SN was analyzed, with a total of six sections for each ani-
mal. The coefficients of error, calculated according to the
procedure of Schmitz and Hof as estimates of precision
[61] varied between 0.07 and 0.16. The conditions of the
experiment were blinded to the investigator. To determine
the terminal density in the striatum pictures of TH stained
sections were taken of 3 sections spaced 250 μm apart and
analyzed using ImageJ. The number of P-S129 α-SYN-
positive neuritic inclusions in the striatum was counted on
a representative section 4 weeks after injection from the
animals of the ‘high α-SYN dose’ experiment.
Knockdown of parkin in SHSY5Y cells
To induce knockdown of parkin in cell culture different
lentiviral vectors expressing a microRNA-based short-
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hairpin RNA (miR) against human parkin were generated
as described [62]. The 2 target sequences resulting in the
most potent knockdown on Q-RT-PCR (data not shown),
miR1 parkin: CCAGAGGAAAGTCACCTGCGAA and
miR2 parkin: ATGTAAAGAAGCGTACCATGAA, were
used for further experiments. A miR against firefly lucifer-
ase is used as control [62]. Human dopaminergic SHSY5Y
neuroblastoma cells stably overexpressing human WT α-
SYN were transduced with lentiviral vectors expressing
the miRs against parkin or control. Cells were maintained
in DMEM (Invitrogen) supplemented with 15% fetal calf
serum (Harlan Sera-Lab, International Medical), 1% non-
essential amino acids (Invitrogen) and 50 μg/ml gentamy-
cin (Invitrogen) and selected with blasticidin (10 μg/ml,
Invitrogen). After selection cell extracts were generated in
1% SDS supplemented with protease cocktail inhibitor
(Roche Diagnostics) and 8.5 μg of protein was loaded
on gel. After electrophoresis and protein transfer the
PVDF membranes (Bio-Rad) were blocked with 5% milk
powder in PBS supplemented with 0.1% Tween 20. The
membranes were incubated with the different primary
antibodies against parkin (4211, 1/1000, Cell Signaling), P-
S129 α-SYN (11A5, 1/2000), α-SYN (15G7, 1/1000, Enzo),
protein phosphatase 2A (1/5000, kind gift of Dr. Veerle
Janssens, Laboratory of Protein Phosphorylation and Pro-
teomics, KU Leuven) and PLK2 (1/500, H-90, Santa Cruz).
All samples were run on the same gel. Detection was
performed after incubation with the appropriate HRP-
conjugated secondary antibodies (Dako) using chemilu-
minescence (ECL+, Pierce).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
5.0 (GraphPad Software, La Jolla, CA, USA). Results are
expressed as means ± standard error of the mean (SEM).
Statistical analysis of the number of TH-positive cells,
the number of Ser-129-P α-SYN positive cells and the
number of α-SYN positive cells was carried out using
two-way analysis of variance (ANOVA) followed by the
Bonferroni post-hoc test for intergroup comparisons. To
compare the number of P-S129 α-SYN positive cells at
the different time points between the two genotypes in
the experiment with the low titer of rAAV2/7-WT α-
SYN, a Student’s T-test was performed and P-values
were adjusted with the Benjamini-Hochberg procedure,
with the false discovery rate set at 0.05, to avoid accu-
mulation of α-errors in multiple T-tests.
Statistical significance level was set as follows: * if P <
0.05, ** if P < 0.01, *** if P < 0.001.
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